Trending...
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- Garage door installation or repair in Minnesota? Which makes more sense for your family?
- Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
PHILADELPHIA, May 4, 2021 /PRNewswire/ -- ExtriCARE USA, a national medical device company specializing in negative pressure wound therapy (NPWT) distribution, is excited to introduce hybrid technology to the wound care market.
The company firmly believes NPWT is still in its infancy stage. There is a tremendous opportunity for growth and innovation because this niche market is evolving. ExtriCARE USA recognizes the potential and is proactively investing in the future of NPWT, which will lead to more positive results for medical equipment providers, clinicians and patients.
ExtriCARE USA has developed a new concept to take the NPWT evolution to the next stage. They plan to positively disrupt the market with hybrid technology that brings versatility to the next level. This concept, coined as hNPWT, will provide patients with a continuum of care necessary to heal wounds more efficiently.
More on The PennZone
Currently, there are two primary applications of NPWT—traditional (tNPWT) and single-use (sNPWT). ExtriCARE USA understands wound healing is not a uniform approach. Through hybrid technology (hNPWT), clinicians can tailor the application based on the patients' distinct needs.
ExtriCARE USA's hybrid model will allow clinicians to be more efficient by simplifying the NPWT process. This hybrid system allows for one pump to utilize both silicon incisional and traditional foam dressing kits. Clinicians will confidently apply which approach will be best suited for the patient.
"Hybrid technology is the future of NPWT," said Peter Mason, President. "Our new product line will be the most adaptable NPWT system in the wound care industry."
When developing new medical devices, it's essential to consider the wide variety of preferences and benefits to all approaches. ExtriCARE USA's hybrid model significantly considers this by giving clinicians the freedom to make their own decisions and work around the patient's needs.
More on The PennZone
ExtriCARE USA is working closely with manufacturer Alleva Medical to design the new product line to bring this hybrid concept to life.
For press inquiries or more information, please contact Binh Nguyen at 717-389-2928 or [email protected].
About ExtriCARE USA:
ExtriCARE USA is a national medical device distribution company specializing in negative pressure wound therapy (NPWT). Our products save clinicians time and benefit patients by introducing solutions that are mobile and provide a more flexible therapy. To learn more, visit www.extricareusa.com.
SOURCE ExtriCARE USA
Related Links
https://extricareusa.com
The company firmly believes NPWT is still in its infancy stage. There is a tremendous opportunity for growth and innovation because this niche market is evolving. ExtriCARE USA recognizes the potential and is proactively investing in the future of NPWT, which will lead to more positive results for medical equipment providers, clinicians and patients.
ExtriCARE USA has developed a new concept to take the NPWT evolution to the next stage. They plan to positively disrupt the market with hybrid technology that brings versatility to the next level. This concept, coined as hNPWT, will provide patients with a continuum of care necessary to heal wounds more efficiently.
More on The PennZone
- Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
- Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
- Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
- Headline: House of Nova Paints Every Face in Gold at New York Fashion Week
- Can Government Operate Better Through Innovation?
Currently, there are two primary applications of NPWT—traditional (tNPWT) and single-use (sNPWT). ExtriCARE USA understands wound healing is not a uniform approach. Through hybrid technology (hNPWT), clinicians can tailor the application based on the patients' distinct needs.
ExtriCARE USA's hybrid model will allow clinicians to be more efficient by simplifying the NPWT process. This hybrid system allows for one pump to utilize both silicon incisional and traditional foam dressing kits. Clinicians will confidently apply which approach will be best suited for the patient.
"Hybrid technology is the future of NPWT," said Peter Mason, President. "Our new product line will be the most adaptable NPWT system in the wound care industry."
When developing new medical devices, it's essential to consider the wide variety of preferences and benefits to all approaches. ExtriCARE USA's hybrid model significantly considers this by giving clinicians the freedom to make their own decisions and work around the patient's needs.
More on The PennZone
- Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
- Her Song Lives On: Remembering Mrs. Darlene Davis Porter
- Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
- Pittsburgh Creators Launch Clever New Children's Book, "The Sock Sleuth!"
- Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th
ExtriCARE USA is working closely with manufacturer Alleva Medical to design the new product line to bring this hybrid concept to life.
For press inquiries or more information, please contact Binh Nguyen at 717-389-2928 or [email protected].
About ExtriCARE USA:
ExtriCARE USA is a national medical device distribution company specializing in negative pressure wound therapy (NPWT). Our products save clinicians time and benefit patients by introducing solutions that are mobile and provide a more flexible therapy. To learn more, visit www.extricareusa.com.
SOURCE ExtriCARE USA
Related Links
https://extricareusa.com
0 Comments
Latest on The PennZone
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
- The Social Capital Revolution Comes to Phoenix!
- Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
- FBI/DoW plot uncovered to hurt Trump/Vance through encouraged "widespread" cybersecurity breaches and racketeering theft of $80m in USDA payments
- Bettingbladet releases H1 2026 report on the Swedish online gambling market
- Garage door installation or repair in Minnesota? Which makes more sense for your family?
- SMACK Fight Week Takes Over Philadelphia
- Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
- European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
- VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
- Spearmint Publishes Full Design of Its Mining Pool Before Building It, Including Legal Drafts
- Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
- Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
- Brewtay Coffee Introduces Specialty Instant Line Designed for High-Velocity Commuters and Travelers
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- Ten Ten Ten Awards Provisional Certification to Cara AI for Home-Based Health Assessments
- IDI Consulting Partners with the American Heart Association to Advance Heart Health Awareness
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Diversity Committee
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)